Summary of the Conference Call Transcript Company Overview - The company discussed is **Yuan Dong Bio** (苑东生物), operating in the pharmaceutical industry, particularly focusing on controlled narcotics and innovative drug development. Key Financial Highlights - **2025 Financial Performance**: - Total revenue: **¥1.331 billion** (down **1.36%**) - Net profit attributable to shareholders: **¥283 million** (up **18.89%**) - Non-recurring net profit: **¥206 million** (up **18.01%**) - Q4 revenue: **¥312 million** (up **0.8%**) - Q4 net profit: **¥63 million** (up **197.2%**) - Q4 non-recurring net profit: **¥33 million** (up **376.9%**) [1][2] - **Adjusted Profit Forecast**: - If stock incentive expenses are excluded, the net profit for 2025 is expected to exceed **¥300 million** [2]. Revenue Drivers and Challenges - Revenue decline attributed to the **10th batch of national procurement**, with three products (Naloxone, Shuqing, and Nortriptyline) expected to drop by over **¥150 million**. - Despite this, products like Nabuphine, Butorphanol, and others are maintaining good growth, leading to overall revenue stability [2]. Profitability and R&D Focus - The company is actively integrating its R&D system and controlling costs for generic drugs and some innovative drugs. - Despite additional R&D expenses from the consolidation of Shanghai Chaoyang, the overall R&D expense ratio is expected to improve, a trend anticipated to continue into 2026 [2]. Future Growth Prospects - **2026 Revenue Expectations**: - Revenue from controlled narcotics is projected to increase from **¥60 million** in 2025 to over **¥200 million**, driven by products like Nabuphine, Butorphanol, Ephedrine, and Oxazepam. - Approval of Acetaminophen-Oxycodone and Morphine-Naloxone is imminent, with participation in annual medical insurance negotiations expected [3]. - **Profit Growth**: - The company is expected to achieve a **20% profit growth** in 2026 [3]. R&D Developments - **Shanghai Chaoyang Platform**: - **HP-001 (IKZF1/3 molecular glue)**: Best-in-class single-agent data, currently in Phase IIa clinical trials with potential for conditional marketing approval. - **HP-002 (BTK PROTAC)**: IND submission expected soon, with preclinical data outperforming competitors. - **HP-003 (VAV1 molecular glue)**: Anticipated to be a new star in autoimmune potential, with Phase II POC data expected in mid-2026 and IND submission planned for H2 2026 [3][4]. - **DAC Platform**: - The company has established a complete targeted protein degradation platform, with competitive advantages in both TPD and DAC fields. The first DAC molecule, HP-004, shows significantly better data than combination therapies and is entering the Pre-IND stage [4].